Compare TMHC & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMHC | PCVX |
|---|---|---|
| Founded | 1936 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.1B |
| IPO Year | 2012 | 2020 |
| Metric | TMHC | PCVX |
|---|---|---|
| Price | $59.27 | $56.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $78.75 | ★ $98.33 |
| AVG Volume (30 Days) | 1.0M | ★ 1.0M |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 7.77 | N/A |
| Revenue | ★ $4,762,059,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.07 | N/A |
| P/E Ratio | $7.58 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $51.90 | $28.09 |
| 52 Week High | $72.27 | $76.61 |
| Indicator | TMHC | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 32.13 | 47.16 |
| Support Level | $57.56 | $42.30 |
| Resistance Level | $60.69 | $57.50 |
| Average True Range (ATR) | 1.60 | 2.85 |
| MACD | -0.79 | -0.77 |
| Stochastic Oscillator | 12.80 | 7.91 |
Taylor Morrison Home Corp is an American residential construction company engaged in residential homebuilding and the development of lifestyle communities. It designs, builds, and sells single and multi-family detached and attached homes in traditionally high growth markets for entry level, move-up, and resort lifestyle buyers. The company has four reportable segments: East, Central, West, and Financial Services. The majority of the company's revenue is derived from its West Segment.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.